Eicosanoids represent a family of active biolipids derived from arachidonic acid primarily
through the action of cytosolic phospholipase A2-α. Three major downstream pathways have …

Lung cancer is the leading cause of cancer death in men and women. Lung adenocarcinoma
(LUAD), represents approximately 40% of all lung cancer cases. Advances in recent years, …

Purpose: FGFR1 copy-number gain (CNG) occurs in head and neck squamous cell cancers
(HNSCC) and is used for patient selection in FGFR-specific inhibitor clinical trials. This study …

Lung cancers bearing oncogenic EML4-ALK fusions respond to targeted tyrosine kinase
inhibitors (TKIs; eg, alectinib), with variation in the degree of shrinkage and duration of …

Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent inherited
nephropathy. To date, therapies alleviating the disease have largely focused on targeting …

The FGFR1 is a therapeutic target under investigation in multiple solid tumors and clinical
trials of selective tyrosine kinase inhibitors (TKI) are underway. Treatment with a single TKI …

Targeting PD-1/PD-L1 is only effective in ∼20% of lung cancer patients, but determinants of
this response are poorly defined. We previously observed differential responses of two …

Background Programmed death 1/programmed death ligand 1 (PD-1/PD-L1) targeted
immunotherapy affords clinical benefit in~ 20% of unselected patients with lung cancer. The factor …

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited
kidney disease and affects 1 in 1,000 individuals. There is accumulating evidence suggesting …

Malignant pleural mesothelioma (MPM) is associated with asbestos exposure and is a cancer
that has not been significantly affected by small molecule-based targeted therapeutics. …